Quadruple Swiss venture investments

Switzerland continues to live up to its reputation as one of the premier hubs for life sciences and technology start-ups in Europe, with a large number of sizeable investment rounds in young Swiss companies completed in the last month. The largest saw TVM leading a CHF 24m funding round for specialty pharmaceuticals company Nitec Pharma, which spun out of Merck in 2004 (page 34).

Another prominent example is the Avaris Venture-led CHF 21m investment into Telormedix SA, which is active in the area of immunotherapeutics (page 34). In addition, there was also a CHF 6m investment into Omnisens by Vinci Capital (page 35), and a CHF 4m funding round for medical tech company Symetis backed by Wellington Partners, alongside existing backers (page 35).

Seen in the broader perspective of a considerable increase in venture investment throughout the DACH region in recent months, Switzerland appears to remain at the forefront of innovation.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Industry
• DACH